MARKET

AVEO

AVEO

Aveo Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.150
-0.100
-2.35%
Closed 16:00 05/18 EDT
OPEN
4.150
PREV CLOSE
4.250
HIGH
4.240
LOW
4.030
VOLUME
171.50K
TURNOVER
86.05K
52 WEEK HIGH
7.59
52 WEEK LOW
3.060
MARKET CAP
143.08M
P/E (TTM)
-3.4466
1D
5D
1M
3M
1Y
5Y
AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference
BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright Glo...
GlobeNewswire · 17h ago
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
It's been a mediocre week for AVEO Pharmaceuticals, Inc. ( NASDAQ:AVEO ) shareholders, with the stock dropping 15% to...
Simply Wall St. · 05/08 12:33
Is AVEO Pharmaceuticals (NASDAQ:AVEO) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Simply Wall St. · 05/06 19:57
Recap: AVEO Pharmaceuticals Q1 Earnings
  AVEO Pharmaceuticals (NASDAQ:AVEO) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/05 13:22
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/05 12:43
AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Misses Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of -15.38% and 1.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 12:35
AVEO Pharmaceuticals Q1 EPS $(0.30) Misses $(0.25) Estimate, Sales $20.92M Beat $20.65M Estimate
AVEO Pharmaceuticals (NASDAQ:AVEO) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.25) by 20 percent. This is a 62.96 percent increase over losses of $(0.81) per share
Benzinga · 05/05 11:15
AVEO Pharmaceuticals GAAP EPS of -$0.30, revenue of $20.9M
AVEO Pharmaceuticals press release (NASDAQ:AVEO): Q1 GAAP EPS of -$0.30. Revenue of $20.9M. FY22 FOTIVDA U.S. net product revenues expectations of between $100.0M and $110.0M to be achieved.
Seekingalpha · 05/05 11:09
More
No Data
Learn about the latest financial forecast of AVEO. Analyze the recent business situations of Aveo Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

60.00%Strong Buy
40.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AVEO stock price target is 15.40 with a high estimate of 19.00 and a low estimate of 12.00.
High19.00
Average15.40
Low12.00
Current 4.150
EPS
Actual
Estimate
-0.36-0.27-0.18-0.09
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 110
Institutional Holdings: 16.96M
% Owned: 49.20%
Shares Outstanding: 34.48M
TypeInstitutionsShares
Increased
14
1.14M
New
12
210.28K
Decreased
16
822.46K
Sold Out
5
106.43K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.80%
Pharmaceuticals & Medical Research
-2.06%
Key Executives
Non-Executive Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Director
Michael Bailey
Chief Financial Officer
Erick Lucera
Chief Operating Officer
Jebediah Ledell
Other
Michael Ferraresso
Independent Director
Kevin Cullen
Independent Director
Corinne Epperly
Independent Director
Anthony Evnin
Independent Director
Gregory Mayes
Independent Director
Scarlett Spring
No Data
No Data
About AVEO
AVEO Pharmaceuticals, Inc. is an oncology biopharmaceutical company that is focused on delivering medicines for patients with cancer. The Company’s products and development program include FOTIVDA, ficlatuzumab, AV-380 and AV-203 AV-203. It develops FOTIVDA in immuno-oncology combinations in refractory renal cell carcinoma (RCC) and other indications and has several other investigational programs in clinical development. The Company markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. The Company’s pipeline of product candidates includes ficlatuzumab, a potent humanized immunoglobulin G1 monoclonalantibody that targets hepatocyte growth factor (HGF). It is also conducting a randomized Phase II confirmatory study of ficlatuzumab for the potential treatment of HNSCC.

Webull offers kinds of AVEO Pharmaceuticals, Inc. stock information, including NASDAQ:AVEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVEO stock methods without spending real money on the virtual paper trading platform.